XML 25 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net earnings/(loss) $ (1,069) $ 497
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:    
Depreciation and amortization 513 603
Impairments and Loss on Sale of Other Investments 3 0
(Gain)/Loss on sale of equity interest in naviHealth (2) 0
Impairments and (gain)/loss on disposal of assets, net 1,764 78
Loss on Extinguishment of Debt 10 1
Share-based compensation 65 84
Provision for bad debts 46 49
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:    
Increase in trade receivables (1,193) (511)
Increase in inventories (922) (1,323)
Increase in accounts payable 1,121 1,267
Other accrued liabilities and operating items, net (206) 1,019
Net cash provided by operating activities 130 1,764
Cash flows from investing activities:    
Proceeds from divestitures and disposal of property and equipment and held for sale assets 934 0
Acquisition of subsidiaries, net of cash acquired 0 (3)
Additions to property and equipment (223) (274)
Purchases of investments (38) (18)
Proceeds from investments 27 5
Proceeds from Hedge, Investing Activities 71 0
Net cash provided by/(used in) investing activities 771 (290)
Cash flows from financing activities:    
Proceeds from interest rate swap terminations 0 18
Reduction of long-term obligations (597) (53)
Net proceeds/(tax withholdings) from share-based compensation (26) (1)
Dividends on common shares (425) (432)
Purchase of treasury shares (1,000) (200)
Net cash used in financing activities (2,048) (668)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations (13) 8
Cash and equivalents reclassified from/(to) assets held for sale 109 (86)
Net increase/(decrease) in cash and equivalents (1,051) 728
Cash and equivalents at beginning of period 3,407 2,771
Cash and equivalents at end of period $ 2,356 $ 3,499